Literature DB >> 20393141

TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10.

David J Huss1, Ryan C Winger, Haiyan Peng, Yuhong Yang, Michael K Racke, Amy E Lovett-Racke.   

Abstract

Myelin-specific effector Th1 cells are able to perpetuate CNS inflammation in experimental autoimmune encephalomyelitis, an animal model representative of multiple sclerosis. Although the effects of cytokines in the CNS microenvironment on naive CD4(+) T cells have been well described, much less is known about their ability to influence Ag-experienced effector cells. TGF-beta is a multifunctioning cytokine present in the healthy and inflamed CNS with well-characterized suppressive effects on naive T cell functions. However, the effects of TGF-beta on effector Th1 cells are not well defined. Using myelin-specific TCR transgenic mice, we demonstrate that TGF-beta elicits differential effects on naive versus effector Th1 cells. TGF-beta enhances cellular activation, proliferation, and cytokine production of effector Th1 cells; however, adoptive transfer of these cells into naive mice showed a reduction in encephalitogenicity. We subsequently demonstrate that the reduced encephalitogenic capacity is due to the ability of TGF-beta to promote the self-regulation of Th1 effector cells via IL-10 production. These data demonstrate a mechanism by which TGF-beta is able to suppress the encephalitogenicity of myelin-specific Th1 effector cells that is unique from its suppression of naive T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393141      PMCID: PMC3804066          DOI: 10.4049/jimmunol.1000288

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Transforming growth factor-beta enhances the in vivo effector function and memory phenotype of antigen-specific T helper cells in experimental autoimmune encephalomyelitis.

Authors:  A D Weinberg; R Whitham; S L Swain; W J Morrison; G Wyrick; C Hoy; A A Vandenbark; H Offner
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

2.  T cells responsive to myelin basic protein in patients with multiple sclerosis.

Authors:  M Allegretta; J A Nicklas; S Sriram; R J Albertini
Journal:  Science       Date:  1990-02-09       Impact factor: 47.728

3.  Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1.

Authors:  L D Johns; K C Flanders; G E Ranges; S Sriram
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

4.  Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1.

Authors:  M K Racke; S Dhib-Jalbut; B Cannella; P S Albert; C S Raine; D E McFarlin
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

Review 5.  Inflammation in the nervous system. Basic mechanisms and immunological concepts.

Authors:  H Lassmann; F Zimprich; K Rössler; K Vass
Journal:  Rev Neurol (Paris)       Date:  1991       Impact factor: 2.607

6.  Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system.

Authors:  K Unsicker; K C Flanders; D S Cissel; R Lafyatis; M B Sporn
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

7.  Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation.

Authors:  D Lindholm; E Castrén; R Kiefer; F Zafra; H Thoenen
Journal:  J Cell Biol       Date:  1992-04       Impact factor: 10.539

8.  Enhanced expression of transforming growth factor beta 1 in the rat brain after a localized cerebral injury.

Authors:  A Logan; S A Frautschy; A M Gonzalez; M B Sporn; A Baird
Journal:  Brain Res       Date:  1992-08-07       Impact factor: 3.252

9.  Localization and actions of transforming growth factor-beta s in the embryonic nervous system.

Authors:  K C Flanders; G Lüdecke; S Engels; D S Cissel; A B Roberts; P Kondaiah; R Lafyatis; M B Sporn; K Unsicker
Journal:  Development       Date:  1991-09       Impact factor: 6.868

10.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Tregs and infections: on the potential value of modifying their function.

Authors:  Sharvan Sehrawat; Barry T Rouse
Journal:  J Leukoc Biol       Date:  2011-09-13       Impact factor: 4.962

2.  CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis.

Authors:  Crisol Álvarez-Quiroga; Carlos Abud-Mendoza; Lesly Doníz-Padilla; Amida Juárez-Reyes; Adriana Monsiváis-Urenda; Lourdes Baranda; Roberto González-Amaro
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

3.  Comprehensive analysis of a mouse model of spontaneous uveoretinitis using single-cell RNA sequencing.

Authors:  Jacob S Heng; Sean F Hackett; Genevieve L Stein-O'Brien; Briana L Winer; John Williams; Loyal A Goff; Jeremy Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

4.  Characterization of regulatory T cell expansion for manufacturing cellular immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Yvonne Y Yee; Dora A Ogbonna; Nisarg J Shah
Journal:  Biomater Sci       Date:  2020-05-22       Impact factor: 6.843

Review 5.  The role of transforming growth factor β in T helper 17 differentiation.

Authors:  Song Zhang
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

Review 6.  TGF-β regulation of encephalitogenic and regulatory T cells in multiple sclerosis.

Authors:  Priscilla W Lee; Mary E Severin; Amy E Lovett-Racke
Journal:  Eur J Immunol       Date:  2017-02-10       Impact factor: 5.532

7.  The rs3761548 FOXP3 variant is associated with multiple sclerosis and transforming growth factor β1 levels in female patients.

Authors:  Tamires Flauzino; Daniela Frizon Alfieri; Wildea Lice de Carvalho Jennings Pereira; Sayonara Rangel Oliveira; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Karen Brajão de Oliveira; Andrea Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Inflamm Res       Date:  2019-08-14       Impact factor: 4.575

8.  Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosis.

Authors:  Priscilla W Lee; Yuhong Yang; Michael K Racke; Amy E Lovett-Racke
Journal:  Brain Behav Immun       Date:  2014-12-10       Impact factor: 7.217

9.  MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis.

Authors:  Mary E Severin; Priscilla W Lee; Yue Liu; Amanda J Selhorst; Matthew G Gormley; Wei Pei; Yuhong Yang; Mireia Guerau-de-Arellano; Michael K Racke; Amy E Lovett-Racke
Journal:  Brain       Date:  2016-04-28       Impact factor: 13.501

Review 10.  Synergistic immunologic targets for the treatment of prostate cancer.

Authors:  Karen M Doersch; Kelvin A Moses; Warren E Zimmer
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.